Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials.
about
Antiplatelet and anticoagulant therapy in elective percutaneous coronary interventionThe Use of Heparin during Endovascular Peripheral Arterial Interventions: A SynopsisDefining optimal activated clotting time for percutaneous coronary intervention: A systematic review and Bayesian meta-regression.Bivalirudin: a review.Antiplatelet and anticoagulant drugs in interventional radiology.Activated clotting time level with weight based heparin dosing during percutaneous coronary intervention and its determinant factorsBivalirudin for percutaneous coronary intervention and in acute coronary syndromes.Risk stratification in non-ST segment elevation acute coronary syndromes with special focus on recent guidelines.Anticoagulant and antiplatelet drugs.Choice of agents to limit the coagulation cascade in acute coronary syndromes.Unfractionated versus fractionated heparin for percutaneous coronary intervention.Heparin dose during percutaneous coronary intervention: how low dare we go?Day-case transfer for percutaneous coronary intervention with adjunctive abciximab in acute coronary syndromesRecommendations on percutaneous coronary intervention for the reperfusion of acute ST elevation myocardial infarction.Antiplatelet therapy in acute coronary syndromes: current agents and impact on patient outcomes.Medical treatment of patients with heart failure or left ventricular dysfunction undergoing percutaneous coronary intervention.Mechanical thrombectomy options in complex percutaneous coronary interventions.Point-of-Care Technologies for Precision Cardiovascular Care and Clinical Research: National Heart, Lung, and Blood Institute Working Group.Anti-platelet and anti-thrombotic approaches in patients undergoing percutaneous coronary intervention.Evolution of anticoagulant and antiplatelet therapy: benefits and risks of contemporary pharmacologic agents and their implications for myonecrosis and bleeding in percutaneous coronary intervention.Optimal anticoagulation during off pump coronary artery bypass in patients recently exposed to clopidogrel.Antithrombotic strategies in non-ST elevation acute coronary syndromes: focus on bivalirudin.Clinical applications of bivalirudin in the cardiac catheterization laboratory.Point-of-care testing for anticoagulation monitoring in neuroendovascular procedures.2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and InterventiSame day discharge after elective percutaneous coronary intervention.Anticoagulation in coronary intervention.Off-pump coronary artery bypass grafting using continuous heparin infusionVascular complications following coronary intervention correlate with long-term cardiac events.Comparison of anti-Xa activity after a single intravenous bolus of low-dose enoxaparin in patients with and without end-stage renal disease.Percutaneous coronary intervention with bivalirudin anticoagulation, immediate sheath removal, and early ambulation: a feasibility study with implications for day-stay procedures.Elective coronary angiography and percutaneous coronary intervention during uninterrupted warfarin therapy.Relationship between the intensity of heparin anticoagulation and clinical outcomes in patients receiving glycoprotein IIb/IIIa inhibitors during primary percutaneous coronary intervention in acute myocardial infarction.Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: The pharmacokinetics of enoxaparin in PCI (PEPCI) study.Current trends in heparin use during arterial vascular interventional radiology.Low-dose heparin for elective percutaneous coronary intervention.The Angio-Seal arterial closure device for early ambulation after elective percutaneous coronary intervention in patients receiving low-dose enoxaparin.High-dose intravenous dalteparin can be monitored effectively using standard coagulation times.Intracoronary macrothrombus formation during percutaneous coronary intervention despite optimal activated clotting time using bivalirudin--a case report.Unfractionated heparin during elective PCI: fixed dose or weight adjusted?
P2860
Q24793199-524A9F33-AC08-4F25-82AF-DD98457B1E76Q26748703-24BC6F29-4B0A-4D5A-AFF6-EA3BFE0D6434Q30248368-A8923C57-4E3D-4996-98B1-A09A19B91A4BQ33367230-C68F740B-1AB4-4CF2-A0A3-AA437C9C27EEQ33395898-58E7B4B7-49A5-46DF-AF3B-5D5B65406C11Q33900654-BC53A080-46AD-4C2C-AF8F-14EDE9EBC160Q34336816-9C9F4EBC-5ADD-49A7-9108-7BABAA11EFA0Q34445660-7CA59130-A103-4483-BCFD-D9C4BAC84BECQ34465106-5E4C23CA-AA0F-4FA8-A738-F5037E119E3FQ34674164-997FEF35-1120-4B76-8240-21732641B72FQ34674179-D6DF36C9-B5FA-4725-83E7-8048E6941DAFQ34858594-B5EDBB74-4ED4-45A7-8AD3-3FFA160554FAQ35579805-D07AA951-063F-4F0C-92A4-4DA836A3FF4DQ35582491-093352D5-5A6A-4BED-A2B9-9AA0CCDF20B4Q36160606-92C69245-3F3D-40CB-B8C5-60C781921842Q36643735-3589EFF5-1170-49F7-9623-C04329E94476Q36645800-73AB360E-5411-4A1F-9B86-28CF8EBF56C4Q36676028-66B05CF2-42B7-4191-90EC-45D1DCC0ABA3Q36920261-A7EC6B11-0DB2-4577-A03C-00985516F9ADQ37070772-21366069-7FAD-4CF5-BC48-F6EB833A3FB2Q37094692-DC0C83EC-E2EB-45D0-A794-01BEF885F6FDQ37608567-3A8F0BC3-F556-417C-8073-5E8C9D041452Q37811622-2ED65176-BD5D-49DA-A868-D77A79F6EB4BQ37932844-17C9C628-D906-4525-9C67-45D3F415C4F2Q37953885-C3C2E17E-2184-48E1-847F-26E3A235B879Q38192516-CF8C077A-35D3-4D95-B4D8-007D85439AD4Q38762278-7CF79499-EEF8-498F-92D3-5AB457BDD540Q40434785-F9AE7AD2-18BA-45FA-B1EF-587D468B5829Q40507081-437FF97E-978A-464D-A3AC-5191221FD167Q43166177-7D7A3E0A-BFB5-40E0-B172-0A44532B586CQ43900387-1163315B-F014-4C2F-B3EF-6767EE1C74CCQ44601542-8A0D604D-18B0-4359-A248-291386FEC982Q44640403-BF0BF715-6614-43E7-AA2B-3C5A3D20F70CQ44750904-0D92C28D-450C-438B-A8B4-F47A9719BA95Q45389704-1D56EAA4-6A97-41DC-ACF4-E284F71333BCQ46112749-D467BEEA-9409-4BF2-B023-5C5FC1D9C0A9Q46334556-C5947986-C039-4E15-A39B-CFAD2C707D6BQ46431021-19F0780F-30A2-4F8A-BD84-D870CE03C55CQ46835630-877E5704-527F-4A8D-87CB-2D98979E3725Q47409928-C5257922-1A49-4FF6-80B9-BE3100246F9A
P2860
Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Defining the optimal activated ...... randomized, controlled trials.
@en
type
label
Defining the optimal activated ...... randomized, controlled trials.
@en
prefLabel
Defining the optimal activated ...... randomized, controlled trials.
@en
P2093
P356
P1433
P1476
Defining the optimal activated ...... randomized, controlled trials.
@en
P2093
D J Moliterno
K E Wolski
S J Brener
P304
P356
10.1161/01.CIR.103.7.961
P407
P577
2001-02-01T00:00:00Z